Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
University of Buenos Aires, Buenos Aires, Argentina.
Acta Ophthalmol. 2020 Mar;98(2):e217-e223. doi: 10.1111/aos.14230. Epub 2019 Aug 17.
To investigate disorganization of retinal inner layers (DRIL) as a biomarker in eyes with diabetic macular oedema (DME) treated by intravitreal dexamethasone (DEX) implant.
Multicentre, retrospective study including eyes with DME treated with DEX implant and follow-up of 12 months after the first injection. OCT scans were evaluated for the presence of DRIL and other structural features. Best corrected visual acuity (BCVA) and central subfield thickness (CST) were recorded at baseline and at 2, 4, 6 and 12 months after treatment. Correlation between DRIL at baseline and outcomes after DEX treatment and the change in DRIL were analysed.
A total of 177 eyes (177 patients; naïve, n = 131; refractory, n = 46) were included. Patients without DRIL at baseline gained significantly more vision and enjoyed greater reduction in CST over 12 months (both p = 0.03). DRIL at the boundary between the ganglion cell-inner plexiform complex and inner nuclear layer improved in 48/64 eyes (75%, p < 0.001), while DRIL between the inner nuclear layer and outer plexiform layer improved in 27/77 eyes (35%, p = 0.004).
This is the first study to show that DEX implant has the potential to ameliorate DRIL. Patients without DRIL at baseline have a favourable outcome. DRIL may serve a robust biomarker in DME treated by DEX implant.
研究糖尿病黄斑水肿(DME)患者经玻璃体内注射地塞米松(DEX)植入物治疗后视网膜内层紊乱(DRIL)作为生物标志物。
本研究为多中心回顾性研究,纳入了接受 DEX 植入物治疗的 DME 患者,并在首次注射后进行了 12 个月的随访。OCT 扫描评估 DRIL 及其他结构特征的存在情况。在基线以及治疗后 2、4、6 和 12 个月记录最佳矫正视力(BCVA)和中央视网膜厚度(CST)。分析基线时 DRIL 与 DEX 治疗后结局的相关性以及 DRIL 的变化。
共纳入 177 只眼(177 例患者;初治,n=131;难治,n=46)。基线时无 DRIL 的患者在 12 个月内视力提高更显著,CST 降低更明显(均 p=0.03)。在节细胞-内丛状层和内核层之间的边界处,64 只眼中有 48 只(75%,p<0.001)的 DRIL 得到改善,而在内核层和外丛状层之间的 77 只眼中有 27 只(35%,p=0.004)的 DRIL 得到改善。
这是第一项表明 DEX 植入物有可能改善 DRIL 的研究。基线时无 DRIL 的患者预后良好。DRIL 可能成为 DEX 植入物治疗 DME 的一种强有力的生物标志物。